Sunday, Apri1 22, 2018, 7:45-11:30 AM
ACPE Approved for 3.5 Contact Hours
Pharmacists are often an underutilized health care resource despite their medication expertise and accessibility. Pharmacists are essential health care providers who are trained to recognize opioid overdose, opioid use disorder, and withdrawal syndromes.
Integration of the pharmacist into medication assisted treatment (MAT) teams for opioid use disorders can help improve access and outcomes, while reducing the risk of relapse. When pharmacists partner with prescribers to provide MAT, pharmacists are able to take the lead in identifying treatment options, developing treatment plans, communicating with patients, improving adherence, monitoring patients, and performing tasks to alleviate prescriber burden.
This session will showcase different practice settings where psychiatric pharmacists partner with prescribers to provide collaborative care for patients with substance use disorders. The learner will leave with knowledge of innovative ways to include pharmacists on the MAT interprofessional team and how to design and execute effective practice protocols. In addition, the learner will explore the pharmacist’s role in addressing controversies and challenges in providing MAT with regard to state and federal level limitations.
Pharmacists participating in this program will be able to:
7:45-9:45 AM |
|
9:45-10:00 AM |
|
10:00-11:30 AM |
|
Registration is available at cpnp.org/register. | Registration Fee |
Member | $115 |
Non-member | $140 |
Resident/Fellow-Member | $99 |
Resident/Fellow-Non-member | $124 |
Student-Member | $99 |
Student-Non-member | $124 |
Registration Includes
|
|
*Early registration fees are available through March 22, 2018. After March 22, 2018, registration fees increase. |
Sarah Melton, PharmD, BCPP, BCACP, FASCP
Sarah T. Melton is Professor of Pharmacy Practice at the Gatton College of Pharmacy at East Tennessee State University (ETSU). She is the Clinical Pharmacist at the Johnson City Community Health Center, the ETSU Center of Excellence for HIV/AIDS, and Highpower, PC. Dr. Melton received her Bachelor of Science in Pharmacy (1991) and Doctor of Pharmacy (1994) degrees from Virginia Commonwealth University/Medical College of Virginia School of Pharmacy (VCU). She completed a Fellowship in Psychiatric Pharmacy at VCU in 1996. She performs comprehensive medication management (CMM) in the areas of psychiatric and neurologic pharmacy, addiction, and other primary care disorders. Melton is recognized nationally for her work in substance abuse most recently with the APhA Generation Rx Award of Excellence acknowledging her commitment to the mission of substance abuse education.
No Relevant Financial Relationships to Disclose
|
|
Christopher M. Jones, PharmD, MPH
Director of the National Mental Health and Substance Use Policy Laboratory
US Department of Health and Human Services
No Relevant Financial Relationships to Disclose Ray Love, PharmD, BCPP, FASHP
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: APhA Workgroup on Medication Administration, NASPA-CPNP Panel on LAIs
Major Stock Shareholder: miscellaneous pharmaceutical stocks controlled by a third party
Troy Moore, PharmD, MS, BCPP No Relevant Financial Relationships to Disclose Bethany DiPaula, PharmD, BCPP No Relevant Financial Relationships to Disclose Gayle Callahan, PharmD, BCPP |